Martijn van Noort (Nelleke Snelder)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 18

Top Topics

Radical Prostatectomy

Epidermal Growth Factor Receptor

Top Venues

CPT: pharmacometrics & systems pharmacology

Journal of pharmacokinetics and pharmacodynamics

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Sebastiaan Camiel Goulooze, Martijn van Noort
Time-varying covariates, overadjustment bias and mediation in pharmacokinetic/pharmacodynamic modeling. CPT: pharmacometrics & systems pharmacology 13 (8) (2024)
Sebastiaan Camiel Goulooze, Martijn van Noort
Time-varying covariates, overadjustment bias and mediation in pharmacokinetic/pharmacodynamic modeling. CPT: pharmacometrics & systems pharmacology 13 (8) (2024)
Sebastiaan Camiel Goulooze, Martijn van Noort
Time-varying covariates, overadjustment bias and mediation in pharmacokinetic/pharmacodynamic modeling. CPT: pharmacometrics & systems pharmacology 13 (8) (2024)
Rolien Bosch, Eric J G Sijbrands, Martijn van Noort
Quantification of the effect of GLP-1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model. CPT: pharmacometrics & systems pharmacology (2024)
Martijn van Noort, Martijn Ruppert, Joost DeJongh, Eleonora Marostica, Rolien Bosch, Emir Mešić, Martijn van Noort
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development. CPT: pharmacometrics & systems pharmacology 13 (7) (2024)
Martijn van Noort, Martijn Ruppert, Joost DeJongh, Eleonora Marostica, Rolien Bosch, Emir Mešić, Martijn van Noort
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development. CPT: pharmacometrics & systems pharmacology (2024)
Martijn van Noort, Martijn Ruppert, Joost DeJongh, Eleonora Marostica, Rolien Bosch, Emir Mešić, Martijn van Noort
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development. CPT: pharmacometrics & systems pharmacology 13 (7) (2024)
Sebastiaan Camiel Goulooze, Martijn van Noort
Time-varying covariates, overadjustment bias and mediation in pharmacokinetic/pharmacodynamic modeling. CPT: pharmacometrics & systems pharmacology (2024)
Martijn van Noort, Martijn Ruppert, Joost DeJongh, Eleonora Marostica, Rolien Bosch, Emir Mešić, Martijn van Noort
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development. CPT: pharmacometrics & systems pharmacology 13 (7) (2024)
Yu Fu, Martijn van Noort, Tingjie Guo, Piet H van der Graaf, Johan G C van Hasselt
Evaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety Studies. Pharmaceutics 15 (4) (2023)
Thomas Eissing, Sebastiaan Camiel Goulooze, Paul van den Berg, Martijn van Noort, Martijn Ruppert, Martijn van Noort, Dirk Garmann, Joerg Lippert, Roland Heinig, Meike Brinker, Hiddo J Lambers Heerspink
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD. Diabetes, obesity & metabolism (2023)
Yu Fu, Martijn van Noort, Tingjie Guo, Piet H van der Graaf, Johan G C van Hasselt
Evaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety Studies. Pharmaceutics 15 (4) (2023)
Yu Fu, Martijn van Noort, Tingjie Guo, Piet H van der Graaf, Johan G C van Hasselt
Evaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety Studies. Pharmaceutics 15 (4) (2023)
Yu Fu, Martijn van Noort, Tingjie Guo, Piet H van der Graaf, Johan G C van Hasselt
Evaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety Studies. Pharmaceutics 15 (4) (2023)
Sebastiaan Camiel Goulooze, Hiddo J Lambers Heerspink, Martijn van Noort, Nelleke Snelder, Meike Brinker, Joerg Lippert, Thomas Eissing
Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD. Clinical pharmacokinetics 61 (7) (2022)
Joost DeJongh, Maurice J Ahsman, Martijn van Noort
A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy. Journal of pharmacokinetics and pharmacodynamics 48 (4) (2021)
Martijn van Noort, Sven Hoefman, Alberto Garcia-Hernandez, Hartmut Onkels, Tobias E Larsson, Kirsten R Bergmann
Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model. Journal of pharmacokinetics and pharmacodynamics 48 (1) (2020)
Martijn van Noort, Henk-Jan Drenth, Kirsten Riber Bergmann, Nolan David Wood, Mark Hibberd, Graham Scott
Population pharmacokinetic-pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin. British journal of clinical pharmacology 85 (6) (2019)